Volontè Silvia, De Vicari Desireè, Cola Alice, Barba Marta, Frigerio Matteo
Ospedale Sant'Anna, ASST Lariana, 22100 Como, Italy.
Faculty of Medicine and Surgery, University of Milano Bicocca, 20126 Monza, Italy.
J Clin Med. 2025 May 29;14(11):3836. doi: 10.3390/jcm14113836.
: Urinary tract infections (UTIs) are the most common bacterial infections and one of the most common diseases worldwide. These infections induce an enormous financial and economic burden. The most frequent pathogen in UTIs is (), which is responsible for over 85% of cases of cystitis and over 60% of recurrent cases. Repeated antibiotic prescriptions increase the risk of bacteria developing resistance, reducing treatment efficacy and limiting long-term therapeutic options. When traditional preventive methods fail to provide protection, other strategies may be necessary. To investigate the effectiveness of vaccination with Uro-Vaxom for the prevention of UTIs based on currently available studies. : Systematic literature search. : The available studies focus almost exclusively on the female sex. Uro-Vaxom decreased the recurrence of UTIs, was overall well tolerated, and reduced the need for antibiotic therapies. : Uro-Vaxom is a potential effective and well-tolerated option for reducing the recurrence of UTIs in patients prone to frequent infections. Nevertheless, the retrospective nature of several studies, combined with methodological limitations and variability in study design, precluded a reliable quantitative estimation of the treatment effect.
尿路感染（UTIs）是最常见的细菌感染之一，也是全球最常见的疾病之一。这些感染造成了巨大的财政和经济负担。尿路感染最常见的病原体是（），它导致了超过85%的膀胱炎病例和超过60%的复发病例。反复开具抗生素处方会增加细菌产生耐药性的风险，降低治疗效果并限制长期治疗选择。当传统预防方法无法提供保护时，可能需要其他策略。基于现有研究调查Uro-Vaxom疫苗预防尿路感染的有效性。：系统文献检索。：现有研究几乎完全集中在女性身上。Uro-Vaxom降低了尿路感染的复发率，总体耐受性良好，并减少了抗生素治疗的需求。：Uro-Vaxom是减少易频繁感染患者尿路感染复发的一种潜在有效且耐受性良好的选择。然而，几项研究的回顾性性质，加上方法学局限性和研究设计的变异性，妨碍了对治疗效果进行可靠的定量估计。
